|John W. Morgan
Chief Executive Officer
Since arriving at HemCon, Morgan has helped the company achieve significant growth and expand its product offering from military to civilian markets. HemCon’s original product, the HemCon® Bandage, was developed in collaboration with the U.S. Army to stop severe, arterial bleeding, the leading cause of death on the battlefield. In 2007, Morgan helped launch the company’s chitosan technology platform in the acute care setting for use in emergency rooms, trauma situations, cardiac catheterization labs and surgery by creating a sales and distribution relationship with Cardinal Health, Inc. HemCon’s technology is also being utilized by general dental practitioners, periodontists and oral surgeons to care for oral trauma and a number of dental procedures.
Prior to joining HemCon, Morgan began his career at Baxter International Inc. where, over the course of 14 years, he worked his way up the ranks from sales representative to president of the mid-American region. Throughout his career, Morgan has held numerous corporate leadership positions including: president-Americas for Regent Medical Products; president and chief executive officer of Epitope, Inc (Nasdaq: EPIT).; and president and chief executive officer at Curon Medical, Inc. (Nasdaq: CURN)
A native of Chicago, IL, Morgan graduated from The University of Arizona with a Bachelor of Science degree in public administration and economics. Mr. Morgan currently serves on the Boards of Directors of AdvaMed, the leading trade association for the medical devices, healthcare diagnostics and healthcare IT industries (Washington D.C.), The Regence Group, Blue Cross/Blue Shield of OR, WA, ID and UT, (Portland, OR), BioQuiddity Inc. (San Francisco, CA), Synedgen Inc. (Los Angeles, CA), The Oregon Innovation Council (Portland, OR), The Coalition for Dwarf Advocacy (Portland, OR) and he is past Chairperson for the Oregon Evergreen Chapter of the Young President’s Organization.
Chief Financial Officer
Nick Hart serves as the chief financial officer for HemCon Medical Technologies. Hart joined the company in 2008 following the acquisition of Alltracel Pharmaceuticals Plc where he was chief financial officer. Prior to this, Hart worked in the life sciences sector for over 20 years, and in the earlier part of his career within a number of manufacturing organizations.
Before joining Alltracel, Hart was chief financial officer of Smart Holograms Ltd., a company developing devices for disease diagnosis and management, and for Bioscience Managers Ltd., an international life sciences corporate finance and advisory practice, advising companies on M&A, strategy, finance and licensing transactions. Prior to those appointments, he was chief financial officer, chief operating officer and acting chief executive officer of Cantab Pharmaceuticals Plc. There, he had numerous financial, corporate and strategic accomplishments including managing Cantab’s IPOs on NASDAQ and the LSE and subsequently leading Cantab’s merger with Xenova Group Plc. Within life sciences, Hart has also worked for BOC Healthcare and Servier, a French pharmaceutical company.
A British citizen, Hart received his bachelor’s degree in Economics and Statistics from Kingston University, London. He is a fellow member of the Institute of Chartered Management Accountants.
As President of HemCon U.S., Block is responsible for all strategic direction and management of operations, product development, sales, marketing, business development and partner alliances. Block also serves as an integral part of the global management team for HemCon Medical Technologies, Inc.
Before joining HemCon, Block gained extensive experience at numerous leading health care and medical technology companies including: Cardinal Health, OraSure Technologies Inc., McKesson HBOC, Baxter International Inc., Allegiance Healthcare and BioTronics Enterprises, Inc. Block's experience spans sales and marketing, direct sales and business development in the medical diagnostic space, and pharmacy dispensing technologies industry.
Block received a Bachelor of Arts in economics from Wake Forest University in Winston-Salem, NC, and was named a Distinguished Military Graduate by the U.S. Army ROTC. Following college, he spent five years on active duty and three years active reserve where he spent time as an Army Ranger / Ranger Instructor.
Simon McCarthy serves as HemCon’s Chief Scientist and is responsible for the research of new products and devices to control bleeding and promote wound repair.
|Simon J. McCarthy, Ph.D.
McCarthy received his undergraduate degree in chemistry and his Ph.D. in polymer chemistry from Monash University in Melbourne, Australia. He has authored or co-authored more than 20 scientific papers and is a co-holder of six patents on polyurethanes and polyesters for biomedical applications.
|Keith Real, Ph.D.
Executive Vice President, Research and Development
An accomplished executive, scientist and scholar, Keith Real is HemCon’s Executive Vice President of Research and Developement. He is responsible for the research and development of new technology platforms and early stage products. Before joining HemCon, he served as Chief Scientific Officer for the Alltracel Group, directing the company’s research and development and technology development divisions. Real was also appointed as Chief Scientific Officer at Nanopeutics s.r.o., Alltracel’s nanotechnology joint venture with Elmarco. From 1999-2004, he had also worked with Alltracel in a contract research capacity. Real has worked as a consultant to other businesses and has served as a new biomedical technology appraiser for government agencies. He has also managed projects for international consortiums of collaborators including universities, regulators, government departments and private companies.
Real obtained a Diploma in Business Finance from the Irish Management Institute, a Bachelor of Science degree in Biochemistry from University College Dublin, and a Ph.D. in Biochemistry from University College Dublin.